Pulse Biosciences
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled vi...
Latest News
11 days ago · marketbeat.com
What Pulse Biosciences (PLSE) Said on Its Q3 Earnings CallPulse Biosciences NASDAQ: PLSE said it completed enrollment ahead of schedule in the pivotal U.S. study of its nPulse Cardiac Catheter, setting up a data readout expected in the third quarter of 2027 as the company increases spending on clinical development and launch preparations.
11 days ago · seekingalpha.com
Pulse Biosciences, Inc. (PLSE) Q3 2026 Earnings Call TranscriptPulse Biosciences, Inc. (PLSE) Q3 2026 Earnings Call Transcript
19 days ago · businesswire.com
Pulse Biosciences to Present at Stifel 2026 Healthcare ConferenceHAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans to participate in the upcoming Stifel 2026 Healthcare Conference in New York, NY. Pulse Biosciences' Management is scheduled to present on Thursday, November 12, at 11:20 am ET. A live and recorded webcast of the presentation will be available on the “Events Calendar and P.
25 days ago · businesswire.com
Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced it will report business updates and financial results for the third quarter 2026 after market close on Thursday, November 5, 2026. Company management will host a corresponding conference call to discuss business updates beginning at 1:30pm PT / 4:30pm ET.Investors interested in l.
1 month ago · businesswire.com
Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid CenterHAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced a partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida. The partnership covers both the commercial use of the nPulse™ Vybrance™ Percutaneous Electrode System in the treatment of patients at the center and a clinical collaboration to.
1 month ago · businesswire.com
Pulse Biosciences' nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced the latest nPulse™ technology advancement will be featured during the 21st Annual International Ventricular Arrhythmias (VT) Symposium 2026, taking place October 9-10 in New York. A presentation at the Symposium will feature preclinical applications of two nPulse prototype endoc.
2 months ago · fool.com
Why Pulse Biosciences Stock Popped TodayAn analyst initiated coverage with an unambiguous buy recommendation. He feels that one market in particular is ripe for disruption by the company.
3 months ago · seekingalpha.com
Pulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call TranscriptPulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call Transcript
3 months ago · marketbeat.com
Pulse Biosciences Q2 Earnings Call HighlightsPulse Biosciences NASDAQ: PLSE reported second-quarter revenue of $434,000 as it accelerated clinical development of its nanosecond pulsed field ablation, or nsPFA, technology, particularly for atrial fibrillation treatment.
3 months ago · zacks.com
Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Misses Revenue EstimatesPulse Biosciences, Inc (PLSE) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.28 per share a year ago.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove PLSE